Due Diligence in 2026: What Healthcare Investors Are Actually Looking For

← Back to All Insights

The diligence landscape has shifted. Not gradually—sharply. Having worked in healthcare consulting since 2012—spanning clinical strategy, regulatory affairs, and commercial advisory across the medical device and life sciences space—I've watched investor expectations evolve in real time. That experience is what drove us to build Vantage Biomedical Partners: the gap between what investors need to evaluate and what traditional diligence actually delivers has never been wider. Financial models and management presentations are no longer sufficient. Investors are demanding clinical adoption evidence, reimbursement pathway validation, and manufacturing scalability data—and they want it before due diligence even starts.

This shift isn't arbitrary. It's a direct response to a painful cycle of post-investment surprises: devices that cleared FDA (Food and Drug Administration) review but stalled at physician adoption, reimbursement pathways that collapsed under CMS (Centers for Medicare & Medicaid Services) policy changes, and manufacturing processes that couldn't scale beyond prototype volumes. The investors who learned these lessons the hard way in 2023–2024 are now building diligence processes designed to catch these failures before capital deploys.

Here are the five diligence categories that now separate successful deals from expensive ones—and what the best-prepared investors and founders are doing differently.

1. Clinical Adoption Evidence: The New Table Stakes

FDA clearance used to be the milestone that mattered most. Clear 510(k) (a premarket submission demonstrating substantial equivalence to a legally marketed device), demonstrate safety and efficacy, go to market. But investors have learned—expensively—that FDA clearance and physician adoption are two entirely different things. A device can have regulatory approval, demonstrated clinical superiority, and clear reimbursement, and still fail because surgeons won't change their workflow to use it.

The question investors are now asking isn't "Is this device cleared?" It's "Will physicians actually use this in their practice, and what's the evidence that they will?"

This means founders need to come to the table with more than clinical trial data. They need real-world adoption metrics: how many physicians have trialed the device outside of a study setting, what the conversion rate is from trial to repeat use, and whether early adopters are expanding their use cases or plateauing. The best-prepared companies are tracking net promoter scores among their clinical users and can articulate specific workflow integration points where their device creates value versus friction.

Our take: Clinical adoption diligence should include direct conversations with 8–12 target end-users who are not on the company's advisory board or invested in its success. Ask them: "Would you use this device in your next 10 cases? What would need to change?" If the answer involves workflow modifications that the company hasn't addressed, that's a material risk regardless of what the clinical data says.

2. Reimbursement Pathway Durability: Beyond Code Verification

CMS reimbursement has always been a diligence item. What's changed is the depth of analysis required. It's no longer sufficient to verify that a CPT (Current Procedural Terminology) or HCPCS (Healthcare Common Procedure Coding System) code exists and that the device is reimbursed at a certain rate. Investors need to assess whether that reimbursement is durable—whether it will survive the next CMS coverage determination cycle, whether commercial payers are following CMS or diverging, and whether the clinical evidence base supporting reimbursement is strong enough to withstand policy review.

This category became urgent after CMS restructured reimbursement for skin substitutes in 2024, cutting rates by roughly 40% across multiple product categories. Companies that had built their entire financial model around pre-2024 reimbursement rates saw valuations collapse overnight. More recently, CMS has been tightening coverage criteria for remote patient monitoring (RPM) devices—a shift that has invalidated the unit economics for dozens of connected device companies that raised capital on RPM reimbursement assumptions.

Our take: Reimbursement durability analysis should be a standalone workstream in any medtech diligence, not a subsection of the regulatory review. The investor should understand: what happens to this company's economics if reimbursement drops 20%? If the answer is "the business model breaks," that's not necessarily a deal-killer—but it's a risk that needs to be priced into the investment, not discovered 18 months post-close.

3. Manufacturing Scalability: The Prototype-to-Production Gap

A device that works at 200 units per month and a device that works at 5,000 units per month are fundamentally different manufacturing challenges. Yet financial models routinely project volume ramps without validating that the manufacturing process, supply chain, and quality systems can support them. This is one of the most consistent diligence gaps in the industry: the assumption that manufacturing is a solved problem because the company has a contract manufacturer and a BOM (bill of materials).

Manufacturing scalability diligence requires evaluating design-for-manufacturability (DFM), not just current production capability. Key questions: Has the device been through a formal DFM review? Are there manual assembly steps that become bottlenecks at scale? What's the current yield rate, and how does yield change at higher volumes? Are there single-source components with long lead times? What capital investment is required to move from current volumes to the volumes in the financial model?

Our take: If a company can't show you validated COGS data from a production run of at least 500 units—not prototype runs, actual production runs with commercial-grade tooling—then the manufacturing cost assumptions in the financial model are speculative. That doesn't mean you shouldn't invest. It means you should model a wider range of COGS outcomes and understand what happens to unit economics at the pessimistic end.

4. Regulatory Pathway Realism: FDA Strategy vs. FDA Wishful Thinking

FDA submission strategy has always been a diligence category. What's changed is the sophistication required to evaluate it. The difference between a realistic regulatory pathway and an aspirational one can be 18–24 months and $3–5M in additional clinical work—and most financial models don't account for this variance.

The most common regulatory diligence gap across the medtech landscape: companies pursuing a 510(k) pathway with a predicate device strategy that may not survive FDA review. The predicate device is "substantially equivalent" on paper, but the target device has a different mechanism of action, a different intended use population, or clinical claims that go beyond what the predicate supports. When FDA pushes back—and they do—the company faces a choice between narrowing their clinical claims (which affects the commercial model) or generating additional clinical evidence (which affects the timeline and budget).

De novo classification requests are another area where diligence frequently reveals unrealistic timelines. Companies project 10–12 month FDA review timelines for de novo submissions, but actual median review times have been running 14–18 months, with significant variance. A 6-month delay in FDA clearance doesn't just push back revenue—it burns cash, extends the runway requirement, and may trigger the need for a bridge round that dilutes existing investors.

Our take: Every medtech diligence should include a regulatory pathway stress test: What happens if FDA requests additional clinical data? What happens if the predicate strategy doesn't hold? What's the timeline and cost for a de novo if the 510(k) fails? Companies that can answer these questions credibly are better prepared than companies that present a single regulatory pathway with no contingency.

5. Competitive Moat Assessment: IP (Intellectual Property) Alone Isn't Enough

Patent portfolios have traditionally been the primary proxy for competitive defensibility in medtech diligence. The problem: patents protect specific claims, not market positions. A strong patent doesn't prevent a competitor from developing a different device that solves the same clinical problem through a different mechanism. And in categories where physician loyalty is driven by workflow integration and clinical familiarity rather than device specifications, a superior patent portfolio may not translate to competitive advantage at all.

The diligence question has shifted from "How strong is the IP?" to "What actually creates switching costs for the end user?" In medtech, switching costs come from four sources: clinical workflow integration (physicians who have built their practice around a device ecosystem), training investment (surgeons who have completed specialized training on a platform), data continuity (connected devices that accumulate patient data over time), and institutional procurement (hospitals that have negotiated GPO (group purchasing organization) contracts around specific device platforms).

A company with moderate IP but deep clinical workflow integration may be more defensible than a company with a strong patent portfolio but shallow adoption. Diligence needs to assess both dimensions—but the competitive moat analysis from most advisory firms focuses almost exclusively on IP landscape mapping and ignores the clinical and operational dimensions of defensibility.

The Investor's Diligence Checklist for 2026

Based on patterns from over a hundred device evaluations and conversations with investors across the medtech ecosystem, here's what we recommend investors require before making a commitment:

1. Clinical adoption validation: Independent assessment of physician willingness to adopt, based on conversations with non-affiliated clinicians in the target specialty. Not market research—clinical workflow analysis.
2. Reimbursement stress test: Sensitivity analysis showing company economics under a 20% reimbursement reduction scenario, with identification of specific CMS policy review triggers that could affect the device category.
3. Manufacturing maturity assessment: Validated COGS data from production-scale runs, DFM review findings, and capital requirements for volume ramp to the levels assumed in the financial model.
4. Regulatory pathway contingency: Documentation of the primary regulatory pathway plus at least one contingency pathway, with timeline and cost implications for each scenario.
5. Competitive defensibility beyond IP: Evidence of switching costs, workflow integration depth, and clinical loyalty metrics alongside the standard IP landscape analysis.

None of these items are unreasonable to request. The companies that can provide them are the ones that have done the work to understand their own risk profile. The companies that can't provide them aren't necessarily bad investments—but the investor should understand that they're pricing in more uncertainty than their financial model suggests.

The Bottom Line

Medtech diligence in 2026 requires clinical and technical depth that financial analysis alone cannot provide. The investors who are consistently finding the best deals—and avoiding the worst ones—are the ones who've expanded their diligence process beyond financial modeling to include the five categories above. They're not spending more on diligence. They're spending differently: augmenting traditional financial and strategic analysis with focused clinical and technical assessment that catches the risks financial models can't see.

For founders, this shift is actually good news. Companies that invest in diligence readiness—building the clinical, manufacturing, and regulatory evidence packages that sophisticated investors now expect—differentiate themselves in a competitive fundraising market. They close faster, negotiate better terms, and build investor relationships grounded in transparency rather than optimism.

"The best diligence doesn't just identify risks. It separates the risks that are manageable from the ones that are structural—and gives investors the confidence to move forward on the deals that deserve capital."

Need a Custom Diligence Assessment?

Vantage conducts clinical and technical diligence across 18 risk categories for healthcare investors, PE firms, and corporate acquirers. Get a comprehensive assessment before your next investment decision.

Schedule Free Discovery Call Download Free Red Flags Guide